{"url_path":"/sec/coag/8-k/2026-05-21/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/2114044/0001193125-26-233375-index.html","accession_number":"0001193125-26-233375","cik":"0002114044","ticker":"COAG","issuer_name":"Hemab Therapeutics Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2114044/0001193125-26-233375-index.html","primary_entity_key":"0002114044","primary_entity_name":"Hemab Therapeutics Holdings, Inc."},"word_count":94,"has_tables":true,"body_markdown":"Item 9.01.\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\nNo.\n\n  \n\nDescription\n\n99.1\n  \n[Press Release issued by Hemab Therapeutics Holdings, Inc. on May 21, 2026](d102408dex991.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nHEMAB THERAPEUTICS HOLDINGS, INC.\n\nDate: May 21, 2026\n \n\n \nBy:\n \n\n/s/ Benny Sørensen, M.D., Ph.D.\n\n \n\n \nName:\n \nBenny Sørensen, M.D., Ph.D.\n\n \n\n \nTitle:\n \nPresident and Chief Executive Officer"}